Extended Partnership Agreement Will Expand Availability Across Europe of Gencurix’ In Vitro Diagnostic (IVD) Assays Using Droplet Digital™ PCR (ddPCR™) for Clinical Testing of Critical Oncology Biomarkers
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, and Gencurix, Inc. (KOSDAQ: 229000), a leading Korean developer of oncology testing solutions, today announced the signing of a strategic agreement establishing Bio-Rad as the exclusive distributor of Gencurix’ CE-IVD Droplex™ digital PCR oncology testing kits throughout Europe.
Under the agreement, Gencurix will leverage Bio-Rad’s established commercial network and clinical diagnostics expertise to expand the availability of its portfolio of Droplex oncology testing kits. Built on Bio-Rad’s ddPCR technology and designed for use with Bio-Rad’s QXDx™ ddPCR Systems, the kits enable highly sensitive mutation detection from formalin-fixed paraffin-embedded (FFPE) and liquid biopsy samples in several major cancer types, including melanoma, colorectal cancer (CRC), and non-small cell lung cancer (NSCLC).
The agreement builds upon the companies’ existing relationship and significantly expands this partnership by enabling the commercialization of oncology diagnostic products across European markets, and it includes provisions for joint marketing activities and collaborative product development initiatives.
“We are proud to partner with Gencurix to expand our ddPCR offering and deliver CE-IVD marked ddPCR oncology diagnostics kits to laboratories across Europe,” said Steve Kulisch, Vice President Product Management, Digital Biology Group, Bio-Rad Laboratories. “This partnership will provide clinical laboratories with access to highly sensitive and reliable molecular tools, supporting compliance while ensuring the highest standards of diagnostic accuracy. Most importantly, Gencurix’ Droplex testing kits, combined with our QXDx ddPCR platform, will enable physicians to make more informed treatment decisions based on biomarker testing, thereby contributing to improved patient outcomes.”
“This newly expanded strategic partnership with Bio-Rad represents a significant milestone for Gencurix, validating the clinical value of our Droplex technology,” said Sang Rae Cho, CEO of Gencurix. “Bio-Rad’s extensive European distribution capabilities and deep expertise in digital PCR technology make them the ideal partner to bring our oncology testing solutions to a broader market. This partnership will accelerate access to our innovative diagnostic tools for oncology applications throughout Europe, supporting improved patient outcomes through precision medicine.”
Visit https://gencurix.com/eng/index.php to learn more about Gencurix’ Droplex kits.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety, and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
About Gencurix
Gencurix Co., Ltd. is a molecular diagnostics company headquartered in Seoul, South Korea, focusing on the development of digital PCR-based diagnostic devices and liquid biopsy platforms. Key products include GenesWell™ BCT for breast cancer prognosis testing and the Droplex™ series used for companion diagnostics and patient stratification across various cancer types, providing advanced diagnostic tools that enable cancer detection, monitoring, and treatment selection through precision medicine approaches. For more information, visit www.GENCURIX.com.
Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
+1 510-356-7909
Gencurix
Seungbeom Choi, Assistant Manager
070-7432-9481
Zyme Communications
Dr. Maria Spyrou
+44 (0) 7707 049 640
